### Appendix A – Guidelines Evaluated

<table>
<thead>
<tr>
<th>Year being evaluated</th>
<th>Year evaluation completed (January to March)</th>
<th>Guidelines evaluated</th>
<th>Guideline Publication Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>2014</td>
<td>2015</td>
<td>Breast Cancer</td>
<td>November 2011</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cervical Cancer</td>
<td>January 2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prostate Cancer</td>
<td>November 2014</td>
</tr>
<tr>
<td>2015</td>
<td>2016</td>
<td>Breast Cancer</td>
<td>November 2011</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cervical Cancer</td>
<td>January 2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prostate Cancer</td>
<td>November 2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Obesity in Adults</td>
<td>February 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Obesity in Children</td>
<td>April 2015</td>
</tr>
<tr>
<td>2016</td>
<td>2017</td>
<td>Breast Cancer</td>
<td>November 2011</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cervical Cancer</td>
<td>January 2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prostate Cancer</td>
<td>November 2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cognitive Impairment</td>
<td>January 2015</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Colorectal Cancer</td>
<td>March 2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lung Cancer</td>
<td>April 2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Developmental Delay</td>
<td>May 2016</td>
</tr>
<tr>
<td>2017</td>
<td>2018</td>
<td>Breast Cancer</td>
<td>November 2011</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cervical Cancer</td>
<td>January 2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prostate Cancer</td>
<td>November 2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Tobacco Smoking in Children and Adolescents</td>
<td>February 2017</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Hepatitis C</td>
<td>April 2017</td>
</tr>
<tr>
<td>2018</td>
<td>2019</td>
<td>Breast Cancer</td>
<td>November 2011</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cervical Cancer</td>
<td>January 2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prostate Cancer</td>
<td>November 2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Impaired Vision</td>
<td>May 2018</td>
</tr>
</tbody>
</table>

Appendix 1, as supplied by the authors. Appendix to: Fahim C, Prasad A, Silveira K, et al. Dissemination and implementation of clinical practice guidelines: a longitudinal, mixed-methods evaluation of the Canadian Task Force on Preventive Health Care's knowledge translation efforts. *CMAJ Open* 2023. doi: 10.9778/cmao.20220121. Copyright © 2023 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at cmajgroup@cma.ca.
<table>
<thead>
<tr>
<th>Year 1</th>
<th>Year 2</th>
<th>Study Title</th>
<th>Publication Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>2019</td>
<td>2020</td>
<td>Asymptomatic Bacteriuria in Pregnancy</td>
<td>July 2018</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Breast Cancer Update</td>
<td>December 2018</td>
</tr>
<tr>
<td>2019</td>
<td>2020</td>
<td>Cervical Cancer</td>
<td>January 2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prostate Cancer</td>
<td>November 2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Breast Cancer Update</td>
<td>December 2018</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Asymptomatic Bacteriuria in Pregnancy</td>
<td>July 2018</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Asymptomatic Thyroid Dysfunction</td>
<td>November 2019</td>
</tr>
<tr>
<td>2020</td>
<td>2021</td>
<td>Cervical Cancer</td>
<td>January 2013</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prostate Cancer</td>
<td>November 2014</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Breast Cancer Update</td>
<td>December 2021</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Asymptomatic Thyroid Dysfunction</td>
<td>November 2021</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Esophageal Cancer</td>
<td>July 2020</td>
</tr>
</tbody>
</table>
Appendix B: Task Force Annual Evaluation Interview Script

Introduction to the Task Force (Factors affecting Reach) (~5 - 10 min)

- How did you first learn about the Task Force?
  - Probes: Were you exposed to the Task Force in medical school or your residency training? If so, what did they teach?
- How do you typically hear about new or updated guidelines?

Experiences with Task Force over time (Effectiveness, factors affecting Adoption) (~5 - 10 min)

(Note to interviewer: For this area of questioning, important to consider survey results – esp. which guidelines they use.)

- Describe the extent to which you use/follow recommendations from the Task Force?
  - Do you intend to change your practice to follow any recommendations from the Task Force, and if so, how do you intend to change your practice?

- When did you first start following recommendations from the Task Force? [*if they do follow TF guidelines]
- Could you describe how you make decisions on which recommendations to use/follow?
  - Probe: When a new Task Force recommendation comes out, how do you make a decision on whether or not to follow it?
- What influences your decision to change your preventive health care practices, such as screening?
  - Probe: Can you describe any instances where you changed your practice because of Task Force recommendations?
  - Probe: Have you ever started following a Task Force recommendation and then stopped?
    - Probe: What made you decide to stop? OR What could make you decide to stop following a recommendation?

Guideline decision making (Effectiveness, factors affecting Adoption) (~5 – 10 min)

- From your perspective, where is the main decision-making power for guideline uptake? Who are the influencers that drive guidelines becoming practice?
  - Probe: The practitioner, colleagues, the practice, leaders in the profession, the professional organization, the government, the public?
- What makes a guideline trustworthy?
  - Probes: What are your trusted sources for guidelines?
  - Probe: In your opinion, how does Task Force compare to other sources for guidelines?
  - Probe: Is Task Force trustworthy? Why or why not?
- What makes a guideline easier to implement?
  - Probe: What makes it difficult to implement?

- When you have multiple sources of conflicting information on a preventive health care topic, how do you evaluate which information to follow?
  - Probe: (Note to interviewer: For this probe, important to consider survey responses.) Think about a topic where the Task Force and provincial guidelines are different. How did you decide which recommendations to follow?
Engaging patients (Factors affecting Implementation) [~ 5 – 10 min]

- In your work setting(s), how are patients engaged in discussions about preventive health care? (if at all?)
  - Probe: How do you engage patients in discussions specifically about Task Force recommendations?
  - Probe: (Do you use Task Force KT tools?) How do you use Task Force KT tools?
- In your work setting(s), who else do you think could engage patients in discussions about Task Force recommendations?
  - Probe: How do you think that would work? What support would those people need to engage patients successfully?
  - Probe: Are there any other members of your health care team who engage patients in these discussions?

Accessing Task Force materials (Suggestions for improving Reach and Implementation) [~5 – 10 min]

- How can the Task Force improve your access to the recommendations and tools?
  - What are the current barriers, if any?
  - What are some recommendations the Task Force could consider to make it easier to access these guidelines/tools?

Final thoughts and thank you

- Do you have anything else you would like to share?

Thank you so much for taking the time to share with us today. We will be processing and mailing your compensation soon. Please know that the payment processing can take a few weeks. If you have any questions about the evaluation, you can contact [name] at [contact info].
Appendix C – Annual Evaluation Survey

Task Force 2020 Annual Evaluation

Start of Block: Screening Survey

Q1 Thank you for your interest in the Canadian Task Force on Preventive Health Care ("Task Force") annual evaluation! Please answer the following questions to determine your eligibility to participate.

Q2 What is your profession? (Select all that apply)

- [ ] Primary care physician (1)
- [ ] Nurse practitioner (2)
- [ ] Nurse (3)
- [ ] Resident (4)
- [ ] Medical student (5)
- [ ] Allied health care professional (e.g. physiotherapist, occupational therapist, physician assistant) (6)
- [ ] Researcher (7)
- [ ] Other, please specify: ____________________________

Skip To: Q6 If What is your profession? (Select all that apply) = Medical student
Skip To: Q6 If What is your profession? (Select all that apply) = Allied health care professional (e.g. physiotherapist, occupational therapist, physician assistant)
Skip To: Q6 If What is your profession? (Select all that apply) = Nurse
Q4 I have conflicts of interest relating to Task Force clinical practice guidelines (e.g., owning shares in a company that sells screening tests).

- Yes (1)
- No (2)

Skip To: Q6 if I have conflicts of interest relating to Task Force clinical practice guidelines (e.g., owning sh... = Yes

Page Break

Q3 Are you practicing primary care in Canada?

- Yes (1)
- No (2)

Skip To: Q6 if Are you practicing primary care in Canada? = No
Skip To: End of Block if Are you practicing primary care in Canada? = Yes

Page Break

Q6 Thank you for your interest in participating in the Canadian Task Force on Preventive Health Care (Task Force) annual evaluation. Unfortunately you are not eligible to participate in this study. If you would like to receive newsletters and announcements from the Task Force, please click here to enter your contact information and be added to our listserv.

Page Break

End of Block: Screening Survey

Start of Block: Letter of Information

Appendix 1, as supplied by the authors. Appendix to: Fahim C, Prashad A, Silveira K, et al. Dissemination and implementation of clinical practice guidelines: a longitudinal, mixed-methods evaluation of the Canadian Task Force on Preventive Health Care's knowledge translation efforts. CMAJ Open 2023. doi: 10.9778/cmao.20220121. Copyright © 2023 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at cmajgroup@cma.ca.
Q9 Do you consent to participate in the Task Force 2020 annual evaluation survey?

- I consent to participate in the annual evaluation survey (0)
- I do not consent to participate in the annual evaluation survey (1)

Skip To: End of Survey if Do you consent to participate in the Task Force 2020 annual evaluation survey? = I do not consent to participate in the annual evaluation survey

End of Block: Letter of Information

Start of Block: Current preventive health care practices

Q10 Please respond to the following questions based on your current preventive health care practices. Please note that preventive health care practices, which include screening, target those who are asymptomatic and not identified as high risk.

Q1 How often do you screen for breast cancer with mammography in a woman aged 40 to 49 years?

- Screen the patient every year (1)
- Screen the patient every two years (2)
- Screen the patient every three years (3)
- Screen the patient every four years (4)
- Do not routinely screen the patient (5)
- Other: __________________________
Q178 How often do you screen for breast cancer with mammography in a woman aged 50 to 69 years?

- Screen the patient every year (1)
- Screen the patient every two years (2)
- Screen the patient every three years (3)
- Screen the patient every four years (4)
- Do not routinely screen the patient (5)
- Other: ________________________________________

Q2 How often do you screen a woman for breast cancer by conducting a clinical breast exam?

- Screen the patient every year (1)
- Screen the patient every two years (2)
- Screen the patient every three years (3)
- Screen the patient every four years (4)
- Do not routinely screen the patient (5)
- Other: ________________________________________

Appendix 1, as supplied by the authors. Appendix to: Fahim C, Prashad A, Silveira K, et al. Dissemination and implementation of clinical practice guidelines: a longitudinal, mixed-methods evaluation of the Canadian Task Force on Preventive Health Care's knowledge translation efforts. CMAJ Open 2023. doi: 10.9778/cmaj.00220121. Copyright © 2023 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at cmajgroup@cmaj.ca.
Q3 With which age groups of women do you routinely discuss the harms and benefits of breast cancer screening? Select all that apply.

- 39 and younger (1)
- 40 to 49 (2)
- 50 to 69 (3)
- 70 to 74 (4)
- 75 and older (5)
- I do not routinely discuss the harms and benefits of screening for breast cancer with patients (6)
Q4 How often do you screen for **cervical cancer** in a woman aged 30 to 69 years?

- Screen the patient every year (1)
- Screen the patient every two years (2)
- Screen the patient every three years (3)
- Screen the patient every four years (4)
- Do not routinely screen the patient (5)
- Other: (6) ________________________________

Q177 How often do you screen for **cervical cancer** in a woman aged 25 to 29 years?

- Screen the patient every year (1)
- Screen the patient every two years (2)
- Screen the patient every three years (3)
- Screen the patient every four years (4)
- Do not routinely screen the patient (5)
- Other: (6) ________________________________

---

Appendix 1, as supplied by the authors. Appendix to: Fahim C, Prashad A, Silveira K, et al. Dissemination and implementation of clinical practice guidelines: a longitudinal, mixed-methods evaluation of the Canadian Task Force on Preventive Health Care's knowledge translation efforts. *CMAJ Open* 2023. doi: 10.9778/cmao.20220121. Copyright © 2023 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at cmajgroup@cma.ca.
Q5 How often do you screen for cervical cancer in a woman younger than 25 years old?

- Screen the patient every year (1)
- Screen the patient every two years (2)
- Screen the patient every three years (3)
- Screen the patient every four years (4)
- Do not routinely screen the patient (5)
- Other: ____________________________

Q6 With which age groups of women do you routinely discuss the harms and benefits of cervical cancer screening? Select all that apply.

- 19 and younger (1)
- 20 to 24 (2)
- 25 to 29 (3)
- 30 to 69 (4)
- 70 and older (5)
- ☒ I do not routinely discuss the harms and benefits of screening for cervical cancer with patients (6)
Q7 With which age groups of men do you routinely discuss the harms and benefits of prostate cancer screening? Select all that apply.

- [ ] 54 and younger (1)
- [ ] 55 to 69 (2)
- [ ] 70 and older (3)
- [x] I do not routinely discuss the harms and benefits of screening for prostate cancer with patients (4)

Q9 How often do you screen for prostate cancer with the PSA test in a man younger than 55 years old?

- [ ] Screen the patient every year (1)
- [ ] Screen the patient every two years (2)
- [ ] Screen the patient every three years (3)
- [ ] Screen the patient every four years (4)
- [ ] Do not routinely screen the patient (5)
- [ ] Other: ________________________________________
Q8 How often do you screen for prostate cancer with the PSA test in a man 55 to 69 years old?

- Screen the patient every year (1)
- Screen the patient every two years (2)
- Screen the patient every three years (3)
- Screen the patient every four years (4)
- Do not routinely screen the patient (5)
- Other: ________________________________

Page Break
Q10 How often do you screen for esophageal adenocarcinoma in patients with chronic gastroesophageal reflux disease?

- Screen the patient every year (1)
- Screen the patient every two years (7)
- Screen the patient every three years (8)
- Screen the patients every four years (10)
- Do not routinely screen the patient (11)
- Other: (6) ________________________________________________

Q11 With which age groups of patients with chronic gastroesophageal reflux disease do you routinely discuss the harms and benefits of screening for esophageal adenocarcinoma?

- 18 and older (1)
- 17 and younger (5)
- I do not routinely discuss the harms and benefits of screening for asymptomatic bacteriuria with pregnant patients (4)
Q12 How often do you screen for thyroid dysfunction in asymptomatic non-pregnant adults?

- Screen the patient every year (1)
- Screen the patient every two years (7)
- Screen the patient every three years (8)
- Screen the patient every four years (9)
- Do not routinely screen the patient (2)
- Other: ________________________________________________

Q13 With which age groups of asymptomatic non-pregnant patients do you routinely discuss the harms and benefits of screening for thyroid dysfunction? Please select all that apply

- 17 and younger (1)
- 18 - 30 (4)
- 31 - 60 (6)
- 61 and older (7)
- ☒ I do not routinely discuss the harms and benefits of screening for thyroid dysfunction with non-pregnant asymptomatic patients (5)
Q14 The CTFPHC grades recommendations as either “strong” or “conditional” according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system.

The Task Force previously used the term “weak recommendation”, but has replaced this with the term “conditional recommendation”, to improve understanding and facilitate implementation of guidance, based on feedback from clinician knowledge users.

“Conditional recommendations” result when the balance between desirable and undesirable effects is small, the quality of evidence is lower, and there is more variability in the values and preferences of individuals.

Q15 Are you aware of the recent change of language from “weak” to “conditional”?

- Yes (1)
- No (4)

Q16 In your experience, does the language change from “weak” to “conditional” help facilitate the implementation of recommendations where the balance between desirable and undesirable effects is small, the quality of evidence is lower, and there is more variability in the values and preferences of individuals?

- Yes (1)
- No (4)
- Not sure (5)

Q17 (Optional) Please describe any additional thoughts you have on how the wording used to describe ‘conditional’ or ‘weak’ recommendations may impact implementation.

____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________
____________________________________________________________________

Appendix 1, as supplied by the authors. Appendix to: Fahim C, Prashad A, Silveira K, et al. Dissemination and implementation of clinical practice guidelines: a longitudinal, mixed-methods evaluation of the Canadian Task Force on Preventive Health Care’s knowledge translation efforts. CMAJ Open 2023. doi: 10.9778/cmao.20220121. Copyright © 2023 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at cmajgroup@cma.ca.
Q18 For the following preventive health topics, please indicate whether you primarily use provincial/territorial or national clinical practice guidelines.

Q19 Breast cancer screening
- Task Force national guideline (1)
- Other national guideline: _____________________________
- Provincial/territorial (3)
- Other guideline: _____________________________
- I do not follow a guideline (5)

Q20 Cervical cancer screening
- Task Force national guideline (1)
- Other national guideline: _____________________________
- Provincial/territorial (3)
- Other guideline: _____________________________
- I do not follow a guideline (5)
Q21 Prostate cancer screening

○ Task Force national guideline (1)
○ Other national guideline: (2) _____________________________
○ Provincial/territorial (3)
○ Other guideline: (4) _____________________________
○ I do not follow a guideline (5)

Q22 Esophageal adenocarcinoma with chronic gastroesophageal reflux disease screening

○ Task Force national guideline (1)
○ Other national guideline: (2) _____________________________
○ Provincial/territorial (3)
○ Other guideline: (4) _____________________________
○ I do not follow a guideline (5)
Q23 Thyroid dysfunction screening

- Task Force national guideline (1)
- Other national guideline: (2) ________________________________
- Provincial/territorial (3)
- Other guideline: (4) ________________________________
- I do not follow a guideline (5)

Page Break
Q24 We will now ask you some questions about the Canadian Task Force for Preventive Health Care (Task Force) guidelines, tools, and resources.

Q25 Which Task Force clinical practice guidelines are you aware of? Select all that apply.

☐ Breast cancer screening update (released December 2018) (9)
☐ Cervical cancer screening (2)
☐ Prostate cancer screening (10)
☐ Esophageal cancer screening (3)
☐ Thyroid dysfunction screening (6)
☐ I am not aware of any of the above Task Force screening guidelines (8)

Skip To: End of Block If Which Task Force clinical practice guidelines are you aware of? Select all that apply. = I am not aware of any of the above Task Force screening guidelines
Q26 How satisfied are you with the following Task Force guideline recommendations?

1 – Not at all satisfied
4 – Neither satisfied nor dissatisfied
7 – Very satisfied.
<table>
<thead>
<tr>
<th>Screening Category</th>
<th>1 (1)</th>
<th>2 (2)</th>
<th>3 (3)</th>
<th>4 (4)</th>
<th>5 (5)</th>
<th>6 (6)</th>
<th>7 (7)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast cancer screening update (released December 2018)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervical cancer screening</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prostate cancer screening</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Esophageal cancer screening</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thyroid dysfunction screening</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I am not aware of any of the above Task Force screening guidelines</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Appendix 1, as supplied by the authors. Appendix to: Fahim C, Prashad A, Silveira K, et al. Dissemination and implementation of clinical practice guidelines: a longitudinal, mixed-methods evaluation of the Canadian Task Force on Preventive Health Care's knowledge translation efforts. *CMAJ Open* 2023. doi: 10.9778/cmajo.20220121. Copyright © 2023 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at cmajgroup@cma.ca.
Q27 Please provide any explanation or comments for your dissatisfaction with Task Force guideline recommendations.

________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________
________________________________________________________________

Display This Question:
If Which Task Force clinical practice guidelines are you aware of? Select all that apply. = Breast cancer screening update (released December 2018)

Q28 Have you changed your practice to align with the Task Force breast cancer guideline update since its release in 2018?

☐ Yes, I have made changes in my practice to specifically align with the Task Force breast cancer screening guideline (1)

☐ No, I have not made changes in my practice to specifically align with the Task Force breast cancer screening guideline (2)

☐ My practice was already consistent with the guideline (e.g. I began practicing after the guideline was released and I’ve always followed the Task Force recommendation, or my practice was already consistent with the Task Force recommendations when this guideline was released) (3)

Display This Question:
If Which Task Force clinical practice guidelines are you aware of? Select all that apply. = Cervical cancer screening
Q29 Have you changed your practice to align with the Task Force cervical cancer screening guideline since its release in 2013?

- Yes, I have changed my practice to align with the updated Task Force cervical cancer screening guideline (1)
- No, I have not changed my practice to align with the updated Task Force cervical cancer screening guideline (5)
- My practice was already consistent with the guideline (e.g. My practice was already consistent with the Task Force recommendations when this guideline was released, or I began practising after the guideline was released and I’ve always followed the Task Force recommendation) (6)

Q30 Have you changed your practice to align with the Task Force prostate cancer screening guideline since its release in 2014?

- Yes, I have changed my practice to align with the Task Force prostate cancer screening guideline (1)
- No, I have not changed my practice to align with the Task Force prostate cancer screening guideline (5)
- My practice was already consistent with the Task Force prostate cancer guideline (e.g. My practice was already consistent with the Task Force recommendations when this guideline was released, or I began practising after the guideline was released and I’ve always followed the Task Force recommendations) (6)

Q31 Have you changed your practice to align with the Task Force esophageal adenocarcinoma screening guideline since its release in 2020?

- Yes, I have made changes in my practice to specifically align with the Task Force esophageal adenocarcinoma screening guideline (1)
- No, I have not made changes in my practice to specifically align with the Task Force esophageal adenocarcinoma screening guideline (2)
- My practice was already consistent with the Task Force esophageal adenocarcinoma screening guideline (e.g. My practice was already consistent with the Task Force recommendations when this guideline was released, or I began practising after the guideline was released and I’ve always followed the Task Force recommendation) (3)
Q32 Have you changed your practice to align with the Task Force thyroid dysfunction screening guideline since its release in 2019?

- Yes, I have made changes in my practice to specifically align with the Task Force thyroid screening guideline (1)
- No, I have not made changes in my practice to specifically align with the Task Force thyroid screening guideline (2)
- My practice was already consistent with the thyroid screening guideline (e.g. My practice was already consistent with the Task Force recommendations when this guideline was released, or I began practising after the guideline was released and I’ve always followed the Task Force recommendation) (3)

Q33 The following table lists the Task Force screening guidelines for which you indicated you have not made changes in your practice to specifically align with the Task Force recommendations. Do you intend to make practice changes to align with any of the following Task Force guidelines?
| Have you changed your practice to align with the Task Force prostate cancer screening guideline s... = No, I have not changed my practice to align with the Task Force prostate cancer screening guideline |
|---|---|---|
| I intend to align my practice with this Task Force guideline (1) | I do not intend to align my practice with this Task Force guideline (2) | I haven’t decided yet (3) |
| ☐ | ☐ | ☐ |

Esophageal adenocarcinoma (1)

| Have you changed your practice to align with the Task Force thyroid dysfunction screening guideline... = No, I have not made changes in my practice to specifically align with the Task Force thyroid screening guideline |
|---|---|---|
| I intend to align my practice with this Task Force guideline (1) | I do not intend to align my practice with this Task Force guideline (2) | I haven’t decided yet (3) |
| ☐ | ☐ | ☐ |

Thyroid dysfunction (2)

| Have you changed your practice to align with the Task Force cervical cancer screening guideline s... = No, I have not changed my practice to align with the updated Task Force cervical cancer screening guideline |
|---|---|---|
| I intend to align my practice with this Task Force guideline (1) | I do not intend to align my practice with this Task Force guideline (2) | I haven’t decided yet (3) |
| ☐ | ☐ | ☐ |

Cervical cancer (3)
Have you changed your practice to align with the Task Force esophageal adenocarcinoma screening guideline...

Prostate cancer (4)

Have you changed your practice to align with the Task Force breast cancer screening guideline update since...

Breast Cancer (5)

End of Block: Use and satisfaction with guidelines

Start of Block: Tools and resources
If Which Task Force clinical practice guidelines are you aware of? Select all that apply. ≠ I am not aware of any of the above Task Force screening guidelines

Q34 Are you aware of or have you used any of the following Task Force tools that accompany the clinical practice guidelines? Select all that apply.

---

Q36 Breast cancer screening update (2018) tools

<table>
<thead>
<tr>
<th>Tool Description</th>
<th>I am aware of this tool (1)</th>
<th>I have used this tool (2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1000-person tool (1)</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>1000-person tool, age 40-49 (2)</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>1000-person tool, age 50-59 (3)</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>1000-person tool, age 60-69 (4)</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>1000-person tool, age 70-74 (5)</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

---

If Which Task Force clinical practice guidelines are you aware of? Select all that apply. = Breast cancer screening update (released December 2018)

---

Display This Question:

If Which Task Force clinical practice guidelines are you aware of? Select all that apply. ≠ I am not aware of any of the above Task Force screening guidelines

---

Display This Question:

If Which Task Force clinical practice guidelines are you aware of? Select all that apply. = Breast cancer screening update (released December 2018)

---

Display This Question:

If Which Task Force clinical practice guidelines are you aware of? Select all that apply. = Cervical cancer screening

---

Appendix 1, as supplied by the authors. Appendix to: Fahim C, Prashad A, Silveira K, et al. Dissemination and implementation of clinical practice guidelines: a longitudinal, mixed-methods evaluation of the Canadian Task Force on Preventive Health Care's knowledge translation efforts. *CMAJ Open* 2023. doi: 10.9778/cmao.20220121. Copyright © 2023 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at cmajgroup@cma.ca.
<table>
<thead>
<tr>
<th>Q46 Cervical cancer screening tools</th>
<th>I am <strong>aware</strong> of this tool (1)</th>
<th>I have <strong>used</strong> this tool (2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinician algorithm (1)</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Clinician FAQ (2)</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Patient algorithm (3)</td>
<td>☐</td>
<td>☐</td>
</tr>
<tr>
<td>Patient FAQ (4)</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>
If Which Task Force clinical practice guidelines are you aware of? Select all that apply. = Prostate cancer screening

<table>
<thead>
<tr>
<th>Q47 Prostate cancer screening tools</th>
<th>I am aware of this tool (1)</th>
<th>I have used this tool (2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinician FAQ (1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient FAQ (2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1000-person tool (3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infographic (4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CTFPHC prostate-specific antigen screening video (5)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

If Which Task Force clinical practice guidelines are you aware of? Select all that apply. = Esophageal cancer screening

<table>
<thead>
<tr>
<th>Q48 Esophageal adenocarcinoma screening tools</th>
<th>I am aware of this tool (1)</th>
<th>I have used this tool (2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinician FAQ (1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient FAQ (2)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

 Appendix 1, as supplied by the authors. Appendix to: Fahim C, Prashad A, Silveira K, et al. Dissemination and implementation of clinical practice guidelines: a longitudinal, mixed-methods evaluation of the Canadian Task Force on Preventive Health Care's knowledge translation efforts. CMAJ Open 2023. doi: 10.9778/cmajo.20220121. Copyright © 2023 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at cmajgroup@cmaj.ca.
Display This Question:
If Which Task Force clinical practice guidelines are you aware of? Select all that apply. = Thyroid dysfunction screening

Q49 Thyroid dysfunction screening tool

I am **aware** of this tool (1) I have **used** this tool (2)

Clinician FAQ (1)

Q50 How do you access the Task Force tools? Select all that apply.

Q51 Digital

- I view them on the Task Force website (1)
- I view them on the Task Force mobile app *(Please note: Task Force mobile app is no longer being updated. Our guidelines and tools are now included in the app QxMD Calculate.)* (2)
- I view them on the QxMD mobile app (3)
Q52 Print

☐ I printed copies for myself (1)

☐ I have printed copies that came with my CMAJ publication (Please note: printed copies of CTFPHC tools are no longer sent with CMAJ publications, as of 2018) (2)

☐ I received laminated copies at a conference (i.e. FMF, MFC) (3)

Q53 Other

________________________________________________________________________

Page Break

Q54 Are you aware of or have you used any of the following resources? Select all that apply

________________________________________________________________________
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>I am <strong>aware</strong> of this resource (1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I have <strong>used</strong> this resource (e.g. read it, referred to it) (2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

**Q62 Please provide any additional comments or feedback you have on the Task Force guidelines, tools, or resources.**

---

Appendix 1, as supplied by the authors. Appendix to: Fahim C, Prashad A, Silveira K, et al. Dissemination and implementation of clinical practice guidelines: a longitudinal, mixed-methods evaluation of the Canadian Task Force on Preventive Health Care's knowledge translation efforts. CMAJ Open 2023. doi: 10.9778/cmaoj.20220121. Copyright © 2023 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at cmajgroup@cma.ca.
Start of Block: Demographics

Q63 What is your gender?

- Male (1)
- Female (2)
- Non-binary (3)
- Prefer to self-describe (4) ___________________________________________
- Prefer not to say (5)
Q64 In which province or territory do you practice?

- British Columbia (1)
- Alberta (2)
- Saskatchewan (3)
- Manitoba (4)
- Ontario (5)
- Quebec (6)
- New Brunswick (7)
- Nova Scotia (8)
- Newfoundland (9)
- Prince Edward Island (10)
- Yukon (11)
- Northwest Territories (12)
- Nunavut (13)
Q65 How old are you?
- 20 to 29 (1)
- 30 to 39 (2)
- 40 to 49 (3)
- 50 to 59 (4)
- 60 to 69 (5)
- 70 to 79 (6)
- 80 or older (7)

Q66 How many years have you been practicing?
- 5 or fewer (1)
- 6 to 10 (2)
- 11 to 15 (3)
- 16 to 20 (4)
- 21 to 25 (5)
- 26 to 30 (6)
- 31 to 35 (7)
- 36 to 40 (8)
- 41 or more (9)
Q67 What is your clinical setting? Select all that apply.

- [ ] Urban (1)
- [ ] Suburban (2)
- [ ] Rural (3)
- [ ] Other, please specify: (4) ______________________________________________

Q68 What language do you primarily practice in (select all that apply)?

- [ ] English (4)
- [ ] French (5)
- [ ] Mandarin (6)
- [ ] Cantonese (7)
- [ ] Punjabi (8)
- [ ] Spanish (9)
- [ ] Other (please specify): (10) ____________________________________________
Q69 What is your clinic type? Select all that apply.

☐ Hospital-based (1)

☐ Community-based (2)

☐ Multidisciplinary clinic (3)

☐ Physician group clinic (4)

☐ Single practitioner clinic (5)

☐ Other, please specify: (6) ____________________________________________

Q179 How did you hear about this survey?

☐ Task Force Newsletter (1)

☐ Email (2)

☐ Twitter (3)

☐ Task Force website (5)

☐ Friend/colleague (6)

☐ Other (please describe); (4) ____________________________________________
Q70 Are you willing to participate in a one hour follow-up interview? The interview will ask you about your experiences with the Task Force and about how you use guidelines in your practice. If you complete an interview, you will receive a $100 honorarium. If you do not want to participate in the interview, you can enter a draw for an iPad.

- Yes, I will participate in an interview (1)
- No, I am not willing to participate in an interview (2)

Q71 Would you like to be entered into the draw to win an iPad? The winner will be drawn randomly in Spring 2021. Your contact information will be kept confidential.

- Yes (1)
- No (2)

Q72 The Canadian Task Force on Preventive Health Care has a mailing list that we use to send occasional emails about our work, including guideline and tool updates. We also send emails to the mailing list to recruit primary care practitioners to review tools and provide input into our research projects. Would you be interested in being added to our mailing list?

- Yes (1)
- No (2)
<table>
<thead>
<tr>
<th>RE-AIM Domain</th>
<th>Parent Node</th>
<th>Child Nodes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reach</td>
<td>What do you hear about CTFPHC&lt;br&gt;Expects what the participants has heard about the CTFPHC, the perception of the CTFPHC</td>
<td>• Neutral&lt;br&gt;• Positive&lt;br&gt;• Negative</td>
</tr>
<tr>
<td></td>
<td>Initial Intro to CTFPHC&lt;br&gt;Expects where the participant was first introduced to the CTFPHC</td>
<td>• Other&lt;br&gt;• Medical School and Residency&lt;br&gt;  o Preceptors&lt;br&gt;  o Colleagues&lt;br&gt;• Dissemination activities&lt;br&gt;  o Newsletter&lt;br&gt;  o KT tools&lt;br&gt;  o Website&lt;br&gt;  o App&lt;br&gt;• Conferences&lt;br&gt;• Colleagues</td>
</tr>
<tr>
<td>Effectiveness</td>
<td>Source of Guidelines&lt;br&gt;The sources from which participants access guidelines</td>
<td>• Other national organization&lt;br&gt;• CTFPHC&lt;br&gt;• No source (general)&lt;br&gt;• Specialist organizations</td>
</tr>
<tr>
<td></td>
<td>Trustworthiness&lt;br&gt;Expects the factors which participants identify as lending to the credibility of guidelines</td>
<td>• Composition of guideline developers (diverse experts)&lt;br&gt;• Conflicts of interest/ bias/ funding&lt;br&gt;• Quality of evidence&lt;br&gt;• Specialist input&lt;br&gt;• Popularity among colleagues&lt;br&gt;• Transparency (methods)&lt;br&gt;• Other</td>
</tr>
<tr>
<td>Adoption</td>
<td>Adoption of Guidelines and Tools&lt;br&gt;Factors which help participants determine their use of guidelines and tools</td>
<td>• Relevance to practice&lt;br&gt;• National vs. provincial vs. international&lt;br&gt;• Practitioner&lt;br&gt;• Avenues for guideline information&lt;br&gt;• Clear and concise&lt;br&gt;• Colleagues&lt;br&gt;• Consensus</td>
</tr>
</tbody>
</table>
| Implementation | Impacting Factors/ Determinants of Use
Explores the barriers and facilitators that impact participants’ implementation of guidelines and tools | • Policies
• Physician values/ preferences
• Patients
• Media
• Clinical experience
• Feasibility
• Evidence

| Use of KT Tools
Participants who have selected as using or not using KT tools | • EMR integration
  • Barrier
  • Facilitator
• Resources
  • Barrier
  • Facilitator
• Ease of use
  • Barrier
  • Facilitator
• Colleagues
  • Barrier
  • Facilitator
• Patients
  • Barrier
  • Facilitator
• Other

| Access to KT Tools
Different avenues of accessing KT tools | • Yes
• No

| Suggestions for Increasing Awareness
Participants’ recommendations for increasing users’ awareness of updated and upcoming guidelines and tools | • Website
• Conferences
• Search engine optimization
• Emails

| Alignment of Practice with Guidelines
Examples of participants’ alignment of practice with existing guidelines | • Alignment examples
• Non-alignment examples

Appendix 1, as supplied by the authors. Appendix to: Fahim C, Prashad A, Silveira K, et al. Dissemination and implementation of clinical practice guidelines: a longitudinal, mixed-methods evaluation of the Canadian Task Force on Preventive Health Care’s knowledge translation efforts. CMAJ Open 2023. doi: 10.9778/cmaj:o.20220121. Copyright © 2023 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at cmajgroup@cma.ca.
<table>
<thead>
<tr>
<th>Maintenance</th>
<th>Recall</th>
</tr>
</thead>
<tbody>
<tr>
<td>How participants hear about new/updated guidelines</td>
<td></td>
</tr>
<tr>
<td>Suggestions for Increasing Awareness</td>
<td></td>
</tr>
<tr>
<td>Participants’ suggestions on strategies to increase practitioners awareness of Task Force guidelines and/or KT tools</td>
<td></td>
</tr>
<tr>
<td>• Website</td>
<td></td>
</tr>
<tr>
<td>• Newsletter</td>
<td></td>
</tr>
<tr>
<td>• Colleagues</td>
<td></td>
</tr>
<tr>
<td>• Conferences</td>
<td></td>
</tr>
<tr>
<td>• Attend conferences</td>
<td></td>
</tr>
<tr>
<td>• Medical school</td>
<td></td>
</tr>
<tr>
<td>• Social media</td>
<td></td>
</tr>
<tr>
<td>• Advertisements</td>
<td></td>
</tr>
</tbody>
</table>